Interleukin 6 in Metastatic Renal Cell Cancer
Author Information
Author(s): JML Stouthard, H Goey, EGE de Vries, PH de Mulder, A Groenewegen, L Pronk, G Stoter, HP Sauerwein, PJM Bakker, CHN Veenhof
Primary Institution: Academic Medical Center, University of Amsterdam
Hypothesis
Can recombinant human interleukin 6 (rhIL-6) have anti-tumour effects in patients with metastatic renal cell cancer?
Conclusion
Recombinant human interleukin 6 can be safely administered on an outpatient basis, but its anti-tumour effects in metastatic renal cancer are limited.
Supporting Evidence
- Two partial remissions were noted among the patients treated.
- Moderate and reversible toxicity was observed, mainly fever and flu-like symptoms.
- Baseline plasma IL-6 concentrations did not correlate with tumour behaviour.
Takeaway
This study tested a medicine called interleukin 6 to see if it could help people with a type of kidney cancer. It didn't work very well, but it was safe to use.
Methodology
Patients received daily subcutaneous injections of rhIL-6 for 42 days, and their responses were evaluated based on tumour measurements.
Limitations
The study had a small sample size and limited anti-tumour responses.
Participant Demographics
Patients aged 18 to 75 with histologically verified metastatic renal cell cancer.
Statistical Information
P-Value
<0.001
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website